Davita-North Glendale is a medicare approved dialysis facility center in Glendale, California and it has 36 dialysis stations. It is located in Los Angeles county at 1505 Wilson Terrace, Suite 190, Glendale, CA, 91206. You can reach out to the office of Davita-North Glendale at (818) 637-8348. This dialysis clinic is managed and/or owned by Davita. Davita-North Glendale has the following ownership type - Profit. It was first certified by medicare in December, 2007. The medicare id for this facility is 552589 and it accepts patients under medicare ESRD program.
| Name | Davita-North Glendale |
|---|---|
| Location | 1505 Wilson Terrace, Suite 190, Glendale, California |
| No. of Dialysis Stations | 36 |
| Medicare ID | 552589 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 1505 Wilson Terrace, Suite 190, Glendale, California, 91206 | |
| (818) 637-8348 | |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
| NPI Number | 1174674386 |
| Organization Name | Glendale Dialysis Center |
| Doing Business As | Dialysis Inc. |
| Address | 1505 Wilson Ter Glendale, California, 91206 |
| Phone Number | (800) 525-9059 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
| NPI Number | 1629200134 |
| Organization Name | North Glendale Dialysis |
| Doing Business As | Total Renal Care Inc |
| Address | 1505 Wilson Ter Glendale, California, 91206 |
| Phone Number | (818) 637-8348 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 70% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 14% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 16% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 63% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 14% |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 68% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 17% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 15% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 70% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 77% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 12% |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 132 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 16 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 235 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 2146 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
| Adult patients getting regular peritoneal dialysis at the center | 11 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 90 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 98 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita-North Glendale with elevated calcium levels.
| Patients with hypercalcemia | 250 |
| Hypercalcemia patient months | 2314 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 262 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 192 |
| Patient months included in arterial venous fistula and catheter summaries | 1503 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 80 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 189 |
| Hospitalization Rate in facility | 230.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 322.4 |
| Hospitalization Rate: Lower Confidence Limit | 173.5 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita-North Glendale were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 33.1 (Worse than Expected) |
| Readmission Rate: Upper Confidence Limit | 40.1 |
| Readmission Rate: Lower Confidence Limit | 26.3 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita-North Glendale get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.8 (Worse than Expected) |
| SIR: Upper Confidence Limit | 2.66 |
| SIR: Lower Confidence Limit | 1.17 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita-North Glendale's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 163 |
| Transfusion Rate in facility | 67 (Worse than Expected) |
| Transfusion Rate: Upper Confidence Limit | 102.5 |
| Transfusion Rate: Lower Confidence Limit | 46.1 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita-North Glendale lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 1020 |
| Mortality Rate in facility | 17.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 20.3 |
| Mortality Rate: Lower Confidence Limit | 14.3 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago
Davita-Glendale Dialysis Location: 1000 E. Palmer Avenue, Glendale, California, 91205 Phone: (818) 241-6382 |
Davita-West Glendale Dialysis Location: 1427 S. Glendale Avenue, Glendale, California, 91205 Phone: (818) 241-0016 |
Davita-North Glendale Location: 1505 Wilson Terrace, Suite 190, Glendale, California, 91206 Phone: (818) 637-8348 |
U.S. Renal Care Verdugo Hills Dialysis Location: 1808 Verdugo Blvd., Suite 200, Glendale, California, 91208 Phone: (818) 790-0712 |
News Archive
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.
Two thirds of cancer patients may receive little or no information about the survival benefits of having palliative chemotherapy before making a decision about treatment, according to a study by researchers at Bristol University published today on bmj.com.
Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.
› Verified 6 days ago